ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$1.65 USD
-0.01 (-0.30%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $1.64 -0.01 (-0.30%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PRQR 1.65 -0.01(-0.30%)
Will PRQR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PRQR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRQR
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
PRQR: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK (GSK) Q1 Earnings and Revenues Surpass Estimates
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
Is ProQR (PRQR) Stock a Solid Choice Right Now?
Other News for PRQR
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
ProQR Shareholders Approve Key Resolutions
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
Buy Rating Affirmed for ProQR on Promising RNA Editing Technology and Solid Financial Footing
ProQR’s Axiomer Platform Technology Shows Promise: Analyst Maintains Buy Rating on Robust Editing Efficacy and Clinical Development Potential